<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kamel HAMIZI1,2, Souhila AOUIDANE3, Ghania BELAALOUI1</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Etoposid-based therapy for severe forms of COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Medical Hypotheses</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://doi.org/10.1016/j.mehy.2020.109826</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">PRE PROOF</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Abstract&lt;br&gt;The new coronavirus infection COVID-19 has quickly become a global health emergency.&lt;br&gt;Mortality is principally due to severe Acute Respiratory Distress Syndrome (ARDS) which&lt;br&gt;relays only on supportive treatment. Numerous pathological, clinical and laboratory findings&lt;br&gt;rise the similarity between moderate to severe COVID-19 and haemophagocytic&lt;br&gt;lymphohistiocytosis (HLH). Etoposide-based protocol including dexametasone is the standard&lt;br&gt;of care for secondary HLH. The protocol has been successfully used in HLHs that are secondary&lt;br&gt;to EBV and H1N1 infections by inducing complete response and pronged survival. These&lt;br&gt;observations prompt to consider this cytotoxic therapy in HLH associated to moderately severe&lt;br&gt;to severe forms of COVID-19.&lt;br&gt;Key words: COVID-19; Haemophagocytic lymphohistiocytosis; HLH; Etoposide</style></abstract></record></records></xml>